FIBROGEN INC - COMMON STOCK

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 4 2021 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 4 2021 04:00:01 提供 Nasdaq GlobeNewswire

FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

06 4 2021 16:50:31 提供 Nasdaq GlobeNewswire

FibroGen Provides Additional Information on Roxadustat

06 4 2021 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

16 3 2021 04:00:00 提供 Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

01 3 2021 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen Provides Regulatory Update on Roxadustat

01 3 2021 13:01:00 提供 Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

18 2 2021 04:00:01 提供 Nasdaq GlobeNewswire

FibroGen to Present at Upcoming Investor Conferences

12 2 2021 04:00:00 提供 Nasdaq GlobeNewswire